Antithrombotics and stent type for primary PCI

The Lancet

Volumn 377, Issue 9784, 2011, Pages 2154-2156

  Mukherjee, Debabrata ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PACLITAXEL;

ANTICOAGULANT THERAPY; BARE METAL STENT; CORONARY STENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART LEFT BUNDLE BRANCH BLOCK; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; MORBIDITY; MORTALITY; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TREATMENT OUTCOME;

EID: 79959769056     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60707-1     Document Type: Note

References (11)

1. WHO Cardiovascular diseases http://www.who.int/cardiovascular-diseases/en 2011 (accessed May 27, 2011).
2. D Mukherjee Implementation of evidence-based therapies for myocardial infarction and survival JAMA 305 2011 1710 1711
3. M Aasa, M Henriksson, M Dellborg et al. Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction-results of the Swedish early decision reperfusion study (SWEDES) trial Am Heart J 160 2010 322 328
4. EC Keeley, JA Boura, CL Grines Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials Lancet 361 2003 13 20 (Pubitemid 36050955)
5. GW Stone, B Witzenbichler, G Guagliumi on behalf of the HORIZONS-AMI Trial Investigators Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial Lancet 2011 10.1016/S0140-6736(11) 60764-2 published online June 13.
6. MA Vink, MT Dirksen, MJ Suttorp et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial JACC Cardiovasc Interv 4 2011 24 29
7. JZ Atary, BL van der Hoeven, SS Liem et al. Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study) Am J Cardiol 106 2010 4 12
8. C Spaulding, E Teiger, P Commeau et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty) JACC Cardiovasc Interv 4 2011 14 23
9. A Kaltoft, H Kelbaek, L Thuesen et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial J Am Coll Cardiol 56 2010 641 645
10. L Mauri, WH Hsieh, JM Massaro, KK Ho, R D'Agostino, DE Cutlip Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 2007 1020 1029 (Pubitemid 46376802)
11. AW Martinez, EL Chaikof Microfabrication and nanotechnology in stent design Wiley Interdiscip Rev Nanomed Nanobiotechnol 3 2011 256 268